PanCAN Chief Scientific & Medical Officer Dr. Anna Berkenblit looks back on the progress made toward better understanding and ...

Jazz Pharmaceuticals announced that the FDA has approved ZIIHERA® (zanidatamab-hrii) on an accelerated basis for the treatment ...

Experts believe poor diet, more ultra-processed foods, obesity and a lack of exercise are playing a role. A long-awaited ...

The PD-L1 IHC 28-8 PharmDx test is used to provide information on PD-L1 expression as a biomarker for patient response to therapies containing anti-PD-1 antibodies.

HistoSonics, the developer and manufacturer of the Edison® Histotripsy System, announced today the first patients with pancreatic tumors were successfully treated in the company sponsored GANNON trial ...

Agilent Technologies Inc. (NYSE: A) today announced the issuing of a Class C companion diagnostic In Vitro Diagnostic ...

ImmunityBio, Inc. (NASDAQ: IBRX), a leading immunotherapy company, today announced that it intends to offer and sell, subject ...

Feasibility Trial Evaluates Safety of Histotripsy to Destroy Pancreatic Tumors MINNEAPOLIS--BUSINESS WIRE--HistoSonics, the developer and ...

ImmunityBio, Inc. (IBRX), an immunotherapy company, on Wednesday priced its previously announced underwritten public offering of ...

ImmunityBio (IBRX) announced that it intends to offer and sell, subject to market and other conditions, shares of its common stock in an ...

From climate disasters to political unrest—and everything in between—2024 was a challenging year already, but for certain ...

Recent cancer treatment breakthroughs include FDA approvals for zenocutuzumab and durvalumab, and sacituzumab tirumotecan gained breakthrough therapy status. In addition, sonodynamic therapy shows ...